## **Product** Data Sheet

## TD-0212

 Cat. No.:
 HY-114412

 CAS No.:
 1073549-10-6 

 Molecular Formula:
  $C_{28}H_{34}FN_3O_4S$ 

Molecular Weight: 527.65

Target: Angiotensin Receptor; Neprilysin

Pathway: GPCR/G Protein; Metabolic Enzyme/Protease

**Storage:** Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	TD-0212 (compound 35) is an orally active dual pharmacology angiotens in II type 1 receptor (AT <sub>1</sub> ) antagonist and neprilysin (NEP) inhibitor, with a pK <sub>i</sub> of 8.9 for AT <sub>1</sub> and a pIC <sub>50</sub> of 9.2 for NEP <sup>[1]</sup> .
IC <sub>50</sub> & Target	pKi: 8.9 (AT <sub>1</sub> ) pIC50: 9.2 (NEP) <sup>[1]</sup> .
In Vitro	TD-0212 (compound 35) provides the enhanced activity of dual AT1/NEP inhibition with a potentially lower risk of angioedema relative to dual ACE/NEP inhibition <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TD-0212 (compound 35) produces blood pressure reductions similar to omapatrilat and combinations of AT1 receptor antagonists and NEP inhibitors in models of renin-dependent and –independent hypertension <sup>[1]</sup> .  MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. McKinnell RM, et al. Discovery of TD-0212, an Orally Active Dual Pharmacology AT1 Antagonist and Neprilysin Inhibitor (ARNI). ACS Med Chem Lett. 2018 Dec 3;10(1):86-91.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA